Pleuromutilin 2-[(diphenylmethyl)thio] acetic acid ester with anti-drug resistant bacteria activity and a method of preparing the same

US11512049B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11512049-B2
Application numberUS-202117239582-A
CountryUS
Kind codeB2
Filing dateApr 24, 2021
Priority dateApr 24, 2021
Publication dateNov 29, 2022
Grant dateNov 29, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A compound with anti-drug resistant bacteria activity having the formula (I):(I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound with anti-drug resistant bacteria activity having the following formula 2. A method of preparing the compound of formula (I) of claim 1 , comprising: reacting a compound of formula (II) with a compound of formula (III) to obtain the compound of formula (I), 3. The method of claim 2 , wherein the reaction of the compound of formula (II) with the compound of formula (III) comprises the following steps: placing the compound of formula (II) and the compound of formula (III), in a molar ratio of 1:1 to 1:1.3, in a reactor; adding an organic solvent and a catalytic amount of triethylamine under a nitrogen atmosphere to obtain a reaction mixture; heating the reaction mixture at 20-60° C. for 3-6 hours; extracting the reaction mixture with ethyl acetate to obtain a crude product; and purifying the crude product on a silica gel chromatography column with petroleum ether and ethyl acetate as an eluent to obtain the compound of formula (I). 4. The method of claim 3 , wherein the organic solvent is selected from the group consisting of toluene, dichloromethane and N,N-dimethylformamide. 5. The method of claim 4 , wherein the organic solvent is dichloromethane. 6. The method of claim 3 , wherein the molar ratio of the compound of formula (II) and the compound of formula (III) is 1:1.1. 7. The method of claim 3 , wherein the reaction mixture is heated at 25° C. 8. The method of claim 3 , wherein the reaction mixture is heated for 5 hours. 9. The method of claim 3 , wherein the eluent is petroleum ether:ethyl acetate=4:1. 10. A method of preparing the compound of formula (I) of claim 1 , comprising: reacting a compound of formula (II) with a compound of formula (IV) to obtain the compound of formula (I): 11. The method of claim 10 , wherein the reaction of the compound of formula (II) with the compound of formula (IV) comprises the following steps: placing the compound of formula (II), a catalyst, and an ionic liquid in a reactor under nitrogen atmosphere, the catalyst being 12-molybdosilicic acid hydrate of formula H 6 Mo 12 O 41 Si; adding the compound of formula (IV) to the reactor to form a reaction mixture; heating the reaction mixture at 20-50° C. for 4-8 hours; placing the reaction mixture in a separating funnel to separate a crude product; purifying the crude product by recrystallization in methanol to obtain the compound of formula (I); and recycling the ionic liquid. 12. The method of claim 11 , wherein the ionic liquid is selected from the group consisting of 1-octyl-3-methylimidazolium and hexafluorophosphate, 1-hexyl-3-methylimidazolium tetrafluoroborate and 1-butyl-3-methylimidazolium tetrafluoroborate of formula [BMIM][BF4]. 13. The method of claim 12 , wherein the ionic liquid is 1-butyl-3-methylimidazolium tetrafluoroborate. 14. The method of claim 11 , wherein the compound of formula (II) and the compound (IV) have a molar ratio of 1:1 to 1:1.3. 15. The method of claim 14 , wherein the molar ratio of the compound of formula (II) and the compound of formula (IV) is 1:1.1. 16. The method of claim 11 , wherein the reaction mixture is heated at 30° C. 17. The method of claim 11 , wherein the reaction mixture is heated for 6 hours.

Assignees

Inventors

Classifications

  • containing rings with more than eight members · CPC title

  • A61P31/04Primary

    Antibacterial agents · CPC title

  • the ring being unsaturated · CPC title

  • C07C323/52Primary

    the carbon skeleton being acyclic and saturated · CPC title

  • Separation; Purification · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11512049B2 cover?
A compound with anti-drug resistant bacteria activity having the formula (I):(I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.
Who is the assignee on this patent?
Zhao Qianqian, Zhao Yuqing, Yang Dan, and 11 more
What technology area does this patent fall under?
Primary CPC classification A61P31/04. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).